scorecardresearch
Saturday, August 16, 2025
TopicNovo Nordisk

Topic: Novo Nordisk

In battle for Indian anti-obesity market, Eli Lilly’s pre-filled pen on one side, Novo Nordisk’s on other

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Eli Lilly announces trial results for world’s 2nd weekly insulin, aims for launch by year-end

New Delhi: There is excitement and hope in the insulin market the world over after U.S. based pharma giant Eli Lilly & Company on...

Ozempic on steroids? Successor that could cut down weight in half the time coming soon

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its effectiveness in obesity management come out in 3 months.

On Camera

SC’s stray dog order lit a match in Delhi. Are they a menace or companions?

The last time this matter flared up was when Delhi Chief Minister Rekha Gupta, in a very similar directive in April, called for the relocation of stray dogs in the capital.

Modi’s ‘Diwali bonanza’ for the common man—next-gen GST reforms, lower tax on daily-use items soon

Finance ministry says the proposed revamp will focus on structural reforms, rate rationalisation & ease of living, & will be deliberated upon in the coming weeks.

What is Project Sudarshan Chakra, announced by Modi from ramparts of Red Fort

The project is meant to be a ‘protective shield that will keep expanding’, the PM said. It is on the lines of the ‘Golden Dome’ announced by Trump, it is learnt.

War of IAF, PAF doctrines: As Pakistan obsesses over numbers, India embraces risk, wins

Now that both IAF and PAF have made formal claims of having shot down the other’s aircraft in the 87-hour war in May, we can ask a larger question: do such numbers really matter?